Investigational Factor Xa Compound: Data Presented At European Heart Meeting

Data from a Phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy, according to researchers at the Duke Clinical Research Institute.

More: continued here

Filed under: Blood on September 8th, 2008